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Abstract 
      Besides corticostriatal projections, the thalamic 
intralaminar nuclei are a major source of glutamatergic 
afferents reaching the basal ganglia input nuclei. Although
the thalamostriatal system is already well characterized 
from the anatomical point of view, the role to be played by
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this pathway within basal ganglia function (both in normal and pathological 
conditions) remains poorly understood. On one hand, neurode- generation 
phenomena restricted to the caudal intralaminar nuclei have been described in 
several neurodegenerative disorders such as Parkinson’s disease, progressive 
supranuclear palsy and Huntington’s disease. On the other hand, after unilateral 
dopaminergic depletion in rodents the caudal intralaminar nuclei are highly 
hyperactive. Indeed, the chemical ablation of the caudal intralaminar nuclei 
prevents the increase of the activity observed in both the basal ganglia output 
nuclei and the subthalamic nucleus (STN) after unilateral dopaminergic depletion. 
These findings suggest that the caudal intralaminar nuclei might be responsible (at 
least partially) for the changes in activity of the STN and basal ganglia output 
nuclei typically seen under circumstances of dopamine removal. These results 
paved the way for the implementation of pioneer clinical experiences focused on 
targeting the caudal intralaminar nuclei with a deep brain stimulation electrode in 
patients suffering from advanced Parkinson’s disease. This approach resulted in 
the alleviation of cardinal symptoms of the disease such as resting tremor, drug-
induced dyskinesias and chronic pain. 
 
Introduction 
 The basic principles behind basal ganglia function and anatomical 
organization are summarized in the “classical” basal ganglia model introduced 
at the beginning of the ‘90s [1-3]. Since then, the basal ganglia model has 
became widely accepted by the scientific community and has led to a 
reappraisal of surgical-based therapies for movement disorders of basal ganglia 
origin [4]. Although somewhat simplistic, this model represents the main basis 
for the modern knowledge of the basal ganglia function, both in normal 
circumstances and under pathological conditions. During the past two decades, 
an overwhelming number of new physiological and anatomical data have been 
made available, and therefore the basal ganglia model has been updated by 
integrating the incoming new experimental evidence [5]. Although the main 
skeleton of the basal ganglia model remains largely preserved, the updated 
basal ganglia model has gained increased complexity over the past few years. 
 
 Briefly, the model is based on the arrival of dopaminergic afferents arising 
from the substantia nigra pars compacta (SNc) to the striatum. At the striatal 
level, dopamine (DA) reaches two different subpopulations of efferent 
neurons. All the striatofugal neurons are GABAergic neurons and express 
different types of DA receptors. Striatofugal neurons expressing D1 receptor 
reach the basal ganglia output nuclei -namely the internal division of the 
globus pallidus (GPi) and the substantia nigra pars reticulata (SNr)- through a 
monosynaptic pathway and therefore this pathway has been called the “direct 
pathway”. By contrast, striatofugal neurons expressing D2 receptors innervate 
Thalamic modulation of basal ganglia circuits 27 
the external division of the globus pallidus (GPe), which in turn project to 
the subthalamic nucleus (STN). Glutamatergic STN neurons innervate both 
the GPi and SNr. This polysynaptic pathway linking successively the 
striatum, GPe, STN and GPi/SNr is named the “indirect pathway”. Both the 
direct and the indirect pathways converge onto the output nuclei, which in 
turn project to the thalamus. An appropriate balance between the direct and 
the indirect pathways results in properly conducted movements, whereas the 
removal of DA from the system provokes an imbalance between both 
pathways, which is ultimately responsible for the typical symptoms that 
characterize movement disorders of basal ganglia origin. The information flow 
coming from the cortex across the basal ganglia, the thalamus and back again 
to the cortex is funneled through five separate, segregated loops [6,7]. 
 
 As stated above, the current model of basal ganglia function is somewhat 
simplistic and incoming new evidences deserve particular attention, requiring 
to be further accommodated within the model. Firstly, DA is supposed to exert 
an excitatory effect onto striatal neurons expressing D1 receptor (the ones 
giving rise to the direct pathway) and an inhibitory effect towards striatal 
neurons with D2 receptors (the ones originating the indirect pathway). Such a 
dual effect of DA on striatofugal neurons is one of the cornerstones of the 
basal ganglia model. It is hard to conciliate this reasoning with new data 
showing that most of the striatofugal neurons in fact contain both D1 and D2 
receptors [8-11] and therefore instead of inducing a net excitatory or inhibitory 
effect on the striatofugal neurons, DA is currently seen as a modulator of the 
interaction between glutamate (GLU) and DA receptors at the striatal level 
[12]. Secondly, efferent neurons located in almost all the basal ganglia nuclei 
are characterized by reaching multiple targeted areas through multiple axon 
collaterals [13] and therefore delineating a complex network connecting 
different basal ganglia structures. Thirdly, it is hard to maintain a role for the 
GPe as a simple relay station between the striatum and the STN. In fact, the 
GPe, GPi and STN could be seen as the vertices of a triangle closely 
interconnected, and this triangle is a key “inside” network modulating basal 
ganglia function [14-16]. Fourthly, there is overwhelming evidence showing 
that the basal ganglia nuclei other than the striatum (such as GPe, GPi and 
STN) also receive a direct DAergic innervation from the SNc and the ventral 
tegmental area (VTA). This pathway is known as the nigroextrastriatal 
projection [17-20]. The net effect of the dopamine on both the nigropallidal 
and nigrosubthalamic pathways is apparently mediated by D1 and D2 
receptors [21-23]. Finally, it is worth noting that transverse circuits directly 
connecting the thalamus with both the striatum and the STN (thalamostriatal 
and thalamosubthalamic pathways) have been largely neglected in most of 
the studies carried out so far in basal ganglia circuitry. 
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Figure 1. Sagittal sections of the brain of Macaca fascicularis stained for 
acetylcholinesterase showing the localization of the different basal ganglia nuclei (Left). 
The panel in the right illustrates the different nuclei of the basal ganglia (color-coded) 
together with the basic circuits linking the basal ganglia, according to the “classic” model 
of basal ganglia function. Abbreviations: external division of the globus pallidus (GPe), 
internal division of the globus pallidus (GPi), pedunculopontine nucleus (PPN), substantia 
nigra pars compacta (SNc), substantia nigra pars reticulata (SNr), subthalamic nucleus 
(STN), anterior commissure (a.c.), internal capsule (i.c.), optic tract (o.t.). 
 
 The present chapter is focused on the position of the caudal intralaminar 
nuclei within the basal ganglia circuits. This review summarizes the current 
knowledge on the thalamic modulation of the basal ganglia function both in 
normal conditions and under circumstances of DA depletion. Emphasis will be 
made in integrating anatomical and physiological data together with pioneer 
surgical experiences. 
 
Brain circuits linking the caudal intralaminar nuclei 
with the basal ganglia 
Thalamostriatal projections 
 Initial data describing the presence of a thalamostriatal pathway were 
provided by Vogt and Vogt [24] and further confirmed by Powell and Cowan 
[25]. The caudal intralaminar nuclei of the thalamus are known to be one of the 
major sources of afferents reaching the striatum [26-39]. Thalamostriatal 
projections arising from the caudal intralaminar nuclei are known to be 
excitatory (mediated by GLU) and are characterized by containing the 
vesicular GLU transporter isoform 2 [40,41]. Both types of striatal efferent 
neurons are approached by thalamic afferents [42] and therefore these afferents 
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may exert a widespread excitatory influence on striatofugal neurons [43-46]. 
Indeed, a closed loop linking successively thalamostriatal afferents reaching 
striatal neurons, which in turn innervate neurons in the output nuclei and then 
project back again to the thalamus through the pallidothalamic pathway has 
been characterized and named as the “Nauta-Mehler loop” [47]. Besides 
targeting striatofugal neurons, thalamostriatal afferents also innervate different 
subtypes of striatal interneurons [36,48-54]. Although the intralaminar nuclei 
are the main sources of glutamatergic thalamic inputs to the striatum [55], 
other thalamic nuclei including the midline, the principal relay and the 
association thalamic nuclei are also important contributors to the 
thalamostriatal pathway [56-63]. Within these nuclei, thalamostriatal 
projections are most likely to be collaterals of thalamocortical projections. 
Nevertheless, when considering the caudal intralaminar nuclei, thalamostriatal 
and thalamocortical projections mainly arise from segregated subpopulations 
of efferent neurons [29,64,65]. At the striatal level, corticostriatal and 
thalamostriatal axons innervate different postsynaptic structures. Axons 
coming from the cortex form asymmetric synapses onto the head of the 
dendritic spines of the striatal medium-spiny neurons (MSN) whereas 
thalamostriatal afferents coming from the caudal intralaminar nuclei displayed 
a marked tendency for making excitatory contacts in the dendritic shafts of 
MSNs [29,53,55,66]. In primates, MSNs projecting to the GPi are known to be 
the preferential postsynaptic target for thalamostriatal projections, whereas 
MSNs originating the indirect pathway became less innervated by 
glutamatergic axons from thalamic sources [39,53]. By contrast, in the rodent 
thalamostriatal system both kinds of MSNs neurons are innervated by axons 
arising from the caudal intralaminar nuclei [37,67-69]. 
 
Thalamosubthalamic projections 
 A substantial thalamic innervation arising from the caudal intralaminar nuclei is 
directed towards the STN. Thalamosubthalamic projections have been reported in 
rats, cats and primates [29,37,67,69,70-73]. The thalamosubthalamic projections are 
topographically organized, since motor-related areas of the STN are innervated by 
afferents arising from the motor parts of the caudal intralaminar nuclei, whereas the 
limbic areas of the caudal intralaminar nuclei project to the limbic-related territories 
of STN [29,67] in both primates and rats. Thalamosubthalamic projections are driven 
by GLU and are excitatory [74,75]. Neurons originating the thalamostriatal and the 
thalamosubthalamic projections remain largely segregated within the caudal 
intralaminar nuclei [32] although there is a subpopulation of thalamostriatal-
projecting neurons that also innervates the STN through axon collaterals [34]. Most 
of the STN efferent neurons innervate both the SNr and GPi [13,76-80]. All kinds of 
STN efferent neurons are massively innervated by thalamic afferents [69]. 
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 It is also well known that the caudal intralaminar nuclei exert a bilateral 
modulation of the STN, e.g. the activity of the one STN nucleus is somewhat 
modulated by afferents coming from the ipsilateral thalamus as well as by crossed 
projections arising from the contralateral caudal intralaminar nuclei. Electro- 
physiological recordings obtained after unilateral drug-induced stimulation or 
inhibition showed opposite changes in the ipsi- and contralateral STNs [75]. The 
anatomical substrate sustaining this bilateral control of STN by the caudal 
intralaminar nuclei has been recently demonstrated, by showing that although the 
ipsilateral thalamic innervation of the STN is by far the most prominent one, 
several fibers arising from the caudal intralaminar nuclei also reach the 
contralateral STN [69]. 
 Besides corticosubthalamic projections, thalamic axons reaching the STN 
are one of the main suppliers of glutamatergic inputs to the STN. Recent 
studies carried out after unilateral DAergic depletion in rats have demonstrated 
that neurons in the caudal intralaminar nuclei innervating the STN are highly     
hyperactive  [81,82].  These   studies   have  paved  the way for   considering the 
  
 
 
Figure 2. The position of the caudal intralaminar nuclei in basal ganglia circuitry 
(modified after ref. #85). Two major transverse loops summarize the influence exerted by 
the caudal intralaminar nuclei on basal ganglia circuits. The “Nauta-Mehler loop” 
(illustrated in orange color) links successively the caudal intralaminar nuclei (CM-Pf 
complex), the striatum, the output nuclei and back to the CM-Pf complex. A second loop 
(drawn in purple) comprises thalamosubthalamic projections linked to subthalamofugal 
projections reaching the output nuclei and then back to CM-Pf. Another transverse loop 
(illustrated in green) comprises the circuits linking STN/GPe/STN, although the 
significance of this loop is beyond the focus of the present review. 
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caudal intralaminar nuclei as a potential candidate explaining –at least 
partially- the increases in activity that are typically observed in the STN after 
DA removal, as will be explained later on in this review. 
 
Thalamopallidal projections 
 Thalamic axons can also gain access to the globus pallidum and the SNr 
[38,73,83,84]. Most of the thalamic afferents reaching the globus pallidum are 
collaterals from the thalamostriatal projection [84]. Finally, it is also worth 
noting that the thalamopallidal projection exhibits a clear topographic pattern 
of distribution parallel to thalamostriatal projections [84]. 
 
Increased activity of the caudal intralaminar nuclei 
after dopamine depletion 
 The well-known hyperactivity of the STN after DA depletion is one of the 
main cornerstones of the basal ganglia model. The model explains the STN 
increased activity as a consequence of decreased inhibition received from GPe 
neurons, the latter due to an increased GABAergic striatopallidal outflow as a 
result of the removal of DA reaching striatofugal neurons originating the 
indirect pathway [1-3]. Despite this reasoning, there is a growing body of 
evidence suggesting that STN hyperactivity might depend on mechanisms 
other than reduced inhibition coming from GPe. For example, model 
predictions are challenged by studies measuring the metabolic activity of GPe 
in both rats and primates by using the messenger encoding for the subunit I of 
cytochrome oxidase (CO-I) as a marker for activity. These studies have found 
increased activity –instead of decreased- in GPe after DA depletion [86]. 
Electrophysiological recordings within the STN and GPe in MPTP-treated 
primates have shown an increased activity of the STN –as expected- together 
with no variations in the GPe activity [87]. Additional data difficult to 
accommodate within the model are the lack of induction of dyskinesias in 
control animals after a GPe blockade [88] as well as the failure to abolish 
levodopa-induced dyskinesias in MPTP-treated monkeys after performing a 
GPe lesion [89]. Furthermore, STN hyperactivity is an early phenomenon 
within the cascade of events taking place after dopamine depletion [90,91]. 
Overall, these data suggested that the reduced GABA levels coming from GPe 
could not be the only explanation for STN hyperactivity. 
 At this point, it is worth noting that the caudal intralaminar nuclei –together 
with the pedunculopontine nucleus- could be seen as an attractive candidate for 
explaining the increased STN activity after dopaminergic removal. With regard 
to this, recent studies carried out in rodents have demonstrated that the neurons 
within the caudal intralaminar nuclei innervating the STN displayed a clear 
increase  in  their  activity  under circumstances  of  DAergic  depletion       [81,82]. 
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Figure 3. Sagittal sections of the brain of Macaca fascicularis stained for 
acetylcholinesterase showing a summary of the main pathways linking the CM-Pf 
complex of the thalamus with the basal ganglia nuclei, both in normal conditions (Left) as 
well as under circumstances of dopaminergic depletion (Right). Both the thalamostriatal 
and the thalamosubthalamic projections are highly hyperactive in Parkinson’s disease (see 
refs. #41 and #81, respectively). The activity of the brain circuits linking CM-Pf with both 
segments of the globus pallidus after dopamine removal has not been elucidated. 
Abbreviations: external division of the globus pallidus (GPe), internal division of the 
globus pallidus (GPi), pedunculopontine nucleus (PPN), substantia nigra pars compacta 
(SNc), substantia nigra pars reticulata (SNr), subthalamic nucleus (STN), anterior 
commissure (a.c.), internal capsule (i.c.), optic tract (o.t.). 
 
These findings led to the design of pioneer surgical experiments lesioning the 
caudal intralaminar nuclei. Lesions performed in control rats with normal DA 
levels showed a deep impact on the activity of almost all basal ganglia nuclei 
[92]. Observed changes are in agreement with the removal of direct 
glutamatergic innervation. When considering rats with a unilateral depletion of 
DA, the lesion of the caudal intralaminar nuclei is highly effective in 
preventing the increase on the activity typically observed in both the STN and 
the output nuclei of the basal ganglia [68].  
 Besides the increased activity of the thalamosubthalamic projections after 
DA depletion, our group has recently demonstrated that this might also be the 
case for the thalamostriatal pathway [40,41]. Using the mRNA expression of 
vGlut2 and CO-I as measured by real-time PCR as markers for activity, we 
have found a marked increase on the expression for both mRNAs within 
thalamostriatal-projecting neurons in the caudal intralaminar nuclei on the    
side  of  the  brain  depleted  with  DA when compared to the contralateral side 
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(a three-fold increase on the expression for vGlut2 mRNA and a two-fold increase 
on the expression for CO-I mRNA). In summary, both the thalamostriatal and the 
thalamosubthalamic pathways are highly hyperactive after DAergic depletion. 
Since both pathways are glutamatergic, there is a situation of GLU overflow 
arising from the caudal intralaminar nuclei and reaching most of the key structures 
of the basal ganglia under circumstances of DA removal. 
 
Degeneration of the caudal intralaminar nuclei in 
neurodegenerative diseases 
 The existence of a primary, non-DAergic neurodegeneration restricted to 
the caudal intralaminar nuclei (CM-Pf complex) in Parkinson’s disease has 
been recently demonstrated by a group of neuropathologists from Sydney 
University [93,94]. A marked degeneration estimated at an average of 50% of 
cell loss has been found in the CM-Pf complex in brains coming from 
necropsies of patients suffering from Parkinson’s disease when compared with 
age-matched controls. This was the first time in which degeneration 
phenomena in Parkinson’s disease has been documented outside the DAergic 
cells in the mesencephalon. Similar degeneration phenomena in the CM-Pf 
complex have also been reported in other neurodegenerative disorders of the 
basal ganglia such as the progressive supranuclear palsy [94] and Huntington’s 
disease [95,96]. When considering animal models of Parkinson’s disease, a 
marked degeneration within the intralaminar nuclei was found both in MPTP-
treated mice [97] and after the delivery of MPP+ in the striatum of 6-OHDA-
treated rats [98]. The observed degeneration is apparently selective for 
thalamostriatal-projecting neurons within the caudal intralaminar nuclei [41], 
while the thalamosubthalamic-projecting neurons appeared to be less 
vulnerable [81]. Overall, cell loss is estimated at an average of 70% within 
thalamostriatal-projecting neurons in rats [41]. 
 
 One of the most important issues here is to ascertain whether thalamic 
degeneration is a phenomenon appearing before or after the degeneration of 
the SNc, as well as to analyze the relationships between both kinds of cell loss, 
if such exists. Thalamic degeneration in CM-Pf is a phenomenon already 
present in the earlier stages of Parkinson’s disease (Hoehn and Yahr’s stages 2-
3) and remains without apparent changes until stage 5 and therefore the cell 
loss observed in CM-Pf complex cannot be taken as an end-stage phenomenon 
[99]. Indeed, data coming from behavioral studies carried out after chemical 
lesion of the caudal intralaminar nuclei in rats treated with 6-OHDA did not 
support the idea that thalamic degeneration is a retrograde change to DAergic 
depletion [99]. Data available suggest that both thalamic and nigral 
degeneration are different phenomena co-existing with each other and without 
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apparent relationship. Nevertheless, there may be another way of explaining 
thalamic degeneration, such as the one suggested by a group of British 
researchers indicating that thalamic nerve cell loss in neurodegenerative 
disorders such as Parkinson or Alzheimer is likely to be an age-related 
phenomenon instead of disease-related [100]. 
 
The caudal intralaminar nuclei as a potential 
surgical target for movement disorders of basal 
ganglia orgin 
 The increased activity of the STN under circumstances of dopaminergic 
depletion is one of the main cornerstones of the basal ganglia model and has 
led to the reappraisal of functional neurosurgical therapies approaching the 
STN as the best target to alleviate most of the motor symptoms that typically 
characterize Parkinson’s disease [4]. Several experimental evidences have 
suggested that the caudal intralaminar nuclei are likely to play a key role 
sustaining STN hyperactivity. Firstly, the thalamosubthalamic projection is 
highly hyperactive in 6-OHDA-depleted rats [81,82]. Secondly, the 
hyperactivity of the STN that typically appears in 6-OHDA-treated rats is 
reverted to baseline levels after performing a chemical ablation of the caudal 
intralaminar nuclei [68]. In summary, the increased activity of the STN is 
currently seen as the result of reduced levels of GABA received from GPe 
together with an increased glutamatergic outflow from the caudal intralaminar 
nuclei. These results pave the way for reconsidering CM-Pf as a potential 
surgical target in Parkinson’s disease, in an attempt to decrease the 
glutamatergic overflow reaching the STN after DAergic removal. 
 
 Pioneer clinical experiences were initially carried out by Benabid’s 
group in France in a series of parkinsonian patients subjected to deep brain 
stimulation (DBS) targeting the ventral intermediodorsal thalamic nuclei 
(Vim). The best results were obtained in those patients in which the 
electrode was placed in CM-Pf instead of Vim [101-103]. Later on, a group 
of German neurosurgeons demonstrated that DBS in CM-Pf is highly 
successful in alleviating cardinal symptoms of Parkinson’s disease such as 
resting tremor and levodopa-induced dyskinesias [104-105]. This approach 
(DBS in CM-Pf) also has beneficial effects for the treatment of severe 
forms of Tourette’s syndrome [106] as well as in patients suffering from 
chronic pain [104,105]. Nevertheless, it is important to keep in mind that 
we are dealing with a brain target that is undergoing severe degeneration 
phenomena. In regards to this, a case report showed a clear deterioration of 
the contralateral bradykinesia and rigidity in one patient treated with DBS 
in CM-Pf [107].  
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 Although we consider that there is a clear rationale supporting the CM-Pf 
as a promising target for surgical therapies of movement disorders, pioneer 
clinical experiences exhibited differential outcomes, ranging from a clear 
benefit to a marked worsening of parkinsonian symptoms. Different clinical 
results probably reflect variations in electrode placement within different 
territories of CM-PF. At this point we conclude that although initially very 
promising data were obtained, more research efforts in relevant animal models 
of Parkinson’s disease such as the MPTP primate model are needed in order to 
better address the usefulness of this target for the treatment of movement 
disorders of basal ganglia origin. 
 
Looking for a role to be played by the caudal 
intralaminar nuclei on the plasticity of striatal 
microcircuits 
 During the past few years, the study of DA-GLU interactions at the level 
of the MSNs has gained increased attention. The repetitive stimulation of the 
corticostriatal fibers resulted in a massive release of GLU and DA in the 
striatum, inducing either long-term potentiation (LTP) or long-term depression 
(LTD) of the excitatory synaptic transmission depending on the involvement of 
different subtypes of GLU receptors [108]. The corticostriatal synaptic 
plasticity is seriously compromised after DAergic depletion, requiring the 
stimulation of DARPP-32 (a small protein presented in high levels in MSNs in 
dyskinetic rats) [109]. In conclusion, the appearance of levodopa-induced 
dyskinesias is related to the abnormal synaptic functioning of the corticostriatal 
transmission [109-112]. 
 At the anatomical level, corticostriatal afferents synapse onto the head of the 
spines of the MSNs, whereas thalamostriatal afferents exhibit a marked preference 
for contacting dendritic shafts of MSNs [55,113]. DAergic nigrostriatal afferents 
make synapses with either the head or the neck of the spines of the MSNs, or with 
the dendritic shaft of MSNs. This microcircuitry was revisited later on, and the 
current knowledge accepts that both thalamostriatal and corticostriatal afferents 
make synapses with the head of the spines of the MSNs, whereas the 
thalamostriatal afferents coming from the caudal intralaminar nuclei are the only 
ones contacting the dendritic shafts of MSNs. Regarding the DAergic nigrostriatal 
innervation, the preferred postsynaptic target for these afferents is the neck of the 
spines of the MSNs [39,114]. 
 The appearance of plastic changes on the spines of the neuronal dendrites 
is widely documented in the basal ganglia and in Parkinson’s disease. 
Increases of up to 30% in spine density have been reported in MSNs at the 
striatal level in rats housed over time in a stimulus-rich environment [115]. 
Normal aging resulted in a marked decrease on spine density in cats and mice 
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[116,117]. After DAergic depletion, a clear decrease in the number of dendritic 
spines, together with an atrophy of the dendrites themselves was initially 
reported in 1988 [118] and confirmed later on by a British group [119-122]. 
Similar phenomena have been nicely documented in postmortem tissue from 
parkinsonian patients [123]. Indeed, the loss of dendritic spines induced a 
breakdown in the number of glutamatergic synapses –presumed corticostriatal- 
innervating the striatal MSNs (20% reduction in the number of glutamatergic 
synapses after DA depletion), therefore suggesting that DA is somewhat 
necessary for the maintenance of glutamatergic transmission at the striatal 
level. Very recently, it has been demonstrated both in rats and mice that the 
breakdown in the glutamatergic innervation of the MSNs under circumstances 
of DAergic depletion is more focused on striatal neurons projecting to the GPe, 
whereas the glutamatergic innervation of the striatal neurons giving rise to the 
direct pathway remains better preserved [124]. 
 During the past few years, our research efforts have been focused on 
analyzing the influences driven by thalamic glutamatergic projections onto 
striatofugal neurons. Striatal projecting neurons giving rise to both the direct 
and indirect pathways are massively innervated by excitatory afferents arising 
from the caudal intralaminar nuclei [37,67,69]. Very recently, we have 
demonstrated the existence of severe degeneration phenomena involving up to 
70% of the thalamostriatal-projecting neurons located in the caudal 
intralaminar nuclei [41]. These results are in agreement with earlier data 
showing similar degeneration phenomena in CM-Pf during Parkinson’s disease 
[93,94]. When trying to analyze the relationships between DA loss and 
thalamic degeneration, a feasible explanation is based on the plastic changes 
occurring at the striatal level, as stated previously. We consider that the loss of 
synaptic spines might have some important impact on the arrival of 
glutamatergic axons from thalamic source, e.g., we can hypothesize that 
thalamic degeneration might be a phenomenon retrograde to the remodeling of 
striatal microcircuits after dopaminergic depletion. 
 Overall, the existence of a marked plasticity within the striatal 
microcircuits after DA removal calls for a reappraisal of the current view of 
Parkinson’s disease, in the sense that this disease cannot be seen as simply 
nigrostriatal damage, since the changes in glutamatergic transmission might 
also play a key role in the pathophysiology of this neurodegenerative disorder. 
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